Phase 3
Completed N=91
Minimally Invasive Thoracic Surgery Intercostal Nerve Block Trial
Thoracic Diseases · Postoperative Pain · Opioid Use Disorder
Source: ClinicalTrials.gov NCT03508830 ↗
Enrolled (actual)
91
Serious AEs
0.0%
Results posted
Jun 2021
Primary outcomePrimary: Average Daily In-Hospital Use of Opioids — 40; 45 Oral Morphine Equivalent per Day
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
The Minimally Invasive Thoracic Surgery Intercostal Nerve Block Trial is a single center, double-blind, randomized, active-comparator controlled clinical trial to assess the analgesic efficacy of intercostal nerve block by Liposomal Bupivacaine versus Standard Bupivacaine in subjects undergoing lung resection by robotic or video-assisted thoracoscopic surgery.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Average Daily In-Hospital Use of Opioids |
40; 45 | — |
| SECONDARY Average Daily In-Hospital Pain Score |
2.7; 3.1 | — |
| SECONDARY Number of Participants With Postoperative Pneumonia |
0; 1 | — |
| SECONDARY Length of Stay |
2.2; 2.3 | — |
Eligibility Criteria
Inclusion Criteria
- Robotic or Video-Assisted Lung Resection for All Indications
Exclusion Criteria
- Additional Thoracic Procedures (beyond lung resection and mediastinal lymphadenectomy)
- Extra-Thoracic Procedures
- Hypersensitivity to Amide Local Analgesia
- Cardiac Conduction Abnormalities
- Hepatic Dysfunction
- Preoperative Neuropathic Pain and/or Preoperative Daily Opioid Usage
Data sourced from ClinicalTrials.gov (NCT03508830). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.